Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 17, 2015
Event: Entry into a Material Definitive Agreement regarding an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key figures include:
- Shares Sold: 13,580,246 shares of Common Stock.
- Offering Price: $4.05 per share.
- Over-Allotment Option: Underwriters exercised a 30-day option to purchase an additional 2,037,036 shares.
- Total Shares Issued: 15,617,282 shares (13,580,246 + 2,037,036).
- Net Proceeds: Approximately $59.1 million (after underwriting discounts, commissions, and estimated offering expenses).
- Debt and Liquidity: The filing does not provide specific data on existing debt levels or liquidity ratios outside of the proceeds from this offering.
Material Changes
The primary material change is the increase in the company's cash position due to the closing of the public offering on February 17, 2015. The filing does not provide comparative financial data (e.g., revenue or profit changes) against prior periods as this is a transactional report, not a periodic earnings report.
Guidance, Outlook, and Risks
Management Commentary: The offering was conducted pursuant to an effective shelf registration statement (Form S-3, No. 333-201171). The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification rights.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard terms of the underwriting agreement. The full text of the agreement is incorporated by reference as Exhibit 1.1.
Investor Verification Checklist
- Verify the final net proceeds of $59.1 million against the total shares issued (15,617,282) and the $4.05 offering price to confirm the deduction of underwriting fees.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants or lock-up periods that may affect future stock liquidity.
- Confirm the use of proceeds as disclosed in the final prospectus supplement referenced in the filing.
- Check subsequent filings for the impact of this capital raise on the company's balance sheet and cash runway.